Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedHematologic malignancies during pregnancy: A reviewChronic myeloid leukemia: reminiscences and dreamsEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyCombination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure.Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitorsPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisChronic Myelogenous Leukemia, Version 1.2014Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review.Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesEffectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.Surrogate end points for long-term outcomes in chronic myeloid leukemia.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.Current and future management of Ph/BCR-ABL positive ALL.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.A review of the European LeukemiaNet recommendations for the management of CML.Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Allogeneic transplantation for CML in the TKI era: striking the right balance.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Second line small molecule therapy options for treating chronic myeloid leukemia.Molecular monitoring of chronic myeloid leukemia: present and future.PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
P2860
Q26738514-82BABC74-7BDF-4D15-AE26-E207D6EBF54BQ26740587-EFD69410-9069-4754-9DE1-097A2E07F958Q26748769-DE723CCE-4602-434E-807E-58399391D528Q26749324-F753AABD-C0B5-47ED-99E2-D27EEA0EA592Q26751285-192626B6-016B-4EC6-894E-D29B355EEECEQ30242015-CF5C493C-3073-447D-ACF6-61E923A07F03Q33423072-F55E8A91-8508-4EAC-AC30-95CEF18A5B0CQ33429973-FBFBACE4-4FAE-494B-BC53-A8640F497212Q33603379-AAD6FCB7-03FA-477D-93F1-32A15A48EB49Q34272887-0F057969-4E64-4E30-95B2-F32BD8E31703Q34522810-594B4C18-5DAB-43E9-AE44-9A08194C89A6Q35071010-EA568B27-614F-42B1-987A-D2A77C5B5119Q35130023-70BAFE01-78F3-4374-BEE7-15C290A66F9AQ35899653-45A2213E-45C5-4E99-A8C2-75ED2FDE4375Q36106559-B9F38FE8-ECD5-4EC2-960D-AA110138F4A2Q36400944-B173D795-3273-4DC5-A2AB-79A2E97F1FCDQ37026032-EB9A4CBE-7AF5-4E7F-9CDA-DE9ED47F94DBQ37579983-1AE412E9-F8D9-4B02-90CF-DF444AE26F37Q37714981-92C4E9E0-42DF-4DDC-85B6-DBFA2E168443Q38079249-800ADC30-885A-4B7B-A226-1529DF6E8D1FQ38148233-CE26451A-0D0D-4082-A273-9210A662D0FAQ38194585-D30F527C-CF34-4C53-98D4-46ACA5A04A5BQ38199143-83B5CF5D-B74C-4218-AE8F-A5DDBA19A841Q38216677-E2273419-AF06-4E61-9425-A63C8B06E468Q38254385-ADC3AD4E-4CCD-4EE4-8A43-C7A4AFB08393Q38392673-FA6F331D-4F50-403B-A6CA-3B7F3756C456Q38392676-881C45CE-4EF2-40DD-95E0-63FC5DDAEF7BQ38436037-5D4B41E7-9BC9-4E75-9CCF-B3EB6BAAA234Q38457554-A09B91BA-2496-4C02-BEE0-BD1EEE521915Q38478174-B5C93F1E-03C1-4705-9D17-64187E0DD52EQ38598820-86FD094F-37A4-495A-8C5F-453296D11106Q38634736-B187D8AC-A251-4B4C-B102-98A90F9D5EB7Q38642952-E869B6C5-03C3-492A-8BFA-CA97D59EA755Q38707841-6A0DB4C2-0742-4322-82A8-DA28035441F6Q38753313-8B8020CD-5361-4E0C-813E-B18C477492C9Q38789049-1B83AF6D-99A0-453D-8A12-DF3E9F771356Q38828713-867D472E-A607-4C4C-BCF7-74D968959BFAQ38940615-BF9E1958-A153-4C8E-97EA-39490B95D709Q40302552-E6DC8D23-5888-4238-9E33-657C9213F9BCQ41038941-D2E8CED0-7EF1-46FB-A681-6377F6678B2F
P2860
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@ast
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@en
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@nl
type
label
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@ast
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@en
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@nl
prefLabel
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@ast
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@en
Nilotinib in imatinib-resistan ...... p results of a phase II study.
@nl
P2093
P2860
P50
P356
P1433
P1476
Nilotinib in imatinib-resistan ...... up results of a phase II study
@en
P2093
G Martinelli
H M Kantarjian
J P Radich
J Pinilla-Ibarz
M Baccarani
N Gattermann
P2860
P2888
P304
P356
10.1038/LEU.2012.181
P577
2012-07-05T00:00:00Z
P5875
P6179
1028369333